Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 2/20 | 0.49 |
| ▸ | MAOB | P27338 | 2/20 | 0.49 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.46 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.45 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.43 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.41 |
| ▸ | MMP2 | P08253 | 1/20 | 0.41 |
| ▸ | MMP3 | P08254 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | LPAR1 | Q92633 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1859871 | 0.92 | CYP19A1 (0.41) | MAOAMAOBFOLH1GRIK1CYP19A1 | |
| SCHEMBL1859888 | 0.88 | MAOB (0.50) | MAOAMAOBFOLH1GRIK1MMP2 | |
| SCHEMBL1859940 | 0.88 | GRIK1 (0.51) | FOLH1GRIK1MMP2MMP3LMNA | |
| SCHEMBL12352716 | 0.87 | CA1 (0.49) | MAOAMAOBFOLH1GRIK1CYP19A1 | |
| SCHEMBL1858600 | 0.85 | GRIK1 (0.54) | FOLH1GRIK1MMP2MMP3LMNA | |
| SCHEMBL1865669 | 0.84 | FAAH (0.48) | FOLH1GRIK1MMP2MMP3KMT2A | |
| SCHEMBL1858681 | 0.82 | CYP1A2 (0.51) | FOLH1SIGMAR1MMP2MMP3LPAR1 | |
| SCHEMBL1860059 | 0.82 | MMP12 (0.53) | GRIK1MMP2MMP3 | |
| SCHEMBL1856222 | 0.82 | OPRK1 (0.49) | GRIK1SIGMAR1 | |
| SCHEMBL1858392 | 0.81 | ALDH1A1 (0.57) | SIGMAR1MMP2MMP3MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110105544-A1 | CARBOXYLIC DERIVATIVES FOR USE IN THE TREATMENT OF CANCER | CRYSTAX PHARMACEUTICALS, S.L. (ES) | 2011-05-05 | — | — | US | disclosed |
| WO-2009080722-A2 | CARBOXYLIC DERIVATIVES FOR USE IN THE TREATMENT OF CANCER | CRYSTAX PHARMACEUTICALS, S.L. (ES) | 2009-07-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110105544-A1 | CARBOXYLIC DERIVATIVES FOR USE IN THE TREATMENT OF CANCER | AKR1C3, TPD52L2, HCCS | MAOA 1663/4885MAOB 976/4885FOLH1 1635/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.